Approved PSMA-PET Imaging Tracer Options for Prostate Cancer

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.